Dr. Yu served as the chairman of the Hong Kong Council for Testing and Certification from January 2016 to December 2021. In addition to that, Dr. Yu serves as a professor at the Neuroscience Research Institute at Peking University since January 2002. Dr. Yu founded the Hong Kong Biotechnology Organization (HKBIO) in September 2009 and the Guangdong - Hong Kong - Macau Greater Bay Area Biotechnology Alliance in December 2017, and has been serving as the president since Dr. Yu's appointment.

Dr. Yu also founded Hong Kong DNA Chips Limited, presently Hai Kang Life Corporation Limited, in May 1999, and has been serving as the president of the board. Dr. Yu was appointed as a Justice of the Peace in July 2016. Dr. Pang, BBS, aged 67, obtained a bachelor of science degree from the University of Manitoba in Canada in 1976, and bachelor of science with honours and doctor of philosophy degrees from the Monash University in Australia in 1978 and 1983 respectively.

Dr. Pang was the Biotechnology Director of the Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region for 20 years. She has over thirty years of experience in the research, development and management of the biotechnology industry. Save as disclosed above, as at the date of this announcement, Dr. Pang: (i) did not hold, and had not in the last three years held any other position in the Company or any of its subsidiaries; (ii) had not held any directorship in other public companies the securities of which are listed in Hong Kong or overseas in the last three years; (iii) had no other major appointments or professional qualifications; (iv) did not have any other relationship with any director, senior management or substantial or controlling shareholder of the Company.

As at the date of this announcement, Dr. Pang did not have and was not deemed to have any interests in any shares or underlying shares of the Company within the meaning of Part XV of the SFO. Mr. Wong, Dr. Yu and Dr. Pang have not entered into any service contract with the Company. Mr. Wong, Dr. Yu and Dr. Pang are not appointed for a fixed term of service, and their directorships are subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the bye-laws of the Company.

Mr. Wong, Dr. Yu and Dr. Pang's remuneration as independent non-executive directors of the Company will be determined by the Board upon the recommendation of the Remuneration Committee by reference to their experience, the overall performance of the Company and the prevailing economic situation and market practice. In light of the above, with effect from 21 November 2023, the composition of the Audit Committee, the Remuneration Committee and the Nomination Committee are as follows: Audit Committee: The Audit Committee shall comprise Mr. Wong (as chairman), Mr. Qian Yinghui, Dr. Yu and Dr. Pang. Remuneration Committee: The Remuneration Committee shall comprise Dr. Yu (as chairman), Mr. Tang Ming, Mr. Wong and Dr. Pang.

Nomination Committee: The Nomination Committee shall comprise Mr. Dong Ming (as chairman), Mr. Wong, Dr. Yu and Dr. Pang.